Abstract
COVID-19 starts as a respiratory disease that can progress to pneumonia, severe acute respiratory syndrome (SARS), and multi-organ failure. Growing evidence suggests that COVID-19 is a systemic illness that primarily injures the vascular endothelium, yet the underlying mechanisms remain unknown. SARS-CoV-2 infection is believed to trigger a cytokine storm that plays a critical role in the pathogenesis of endothelialitis and vascular injury, eventually leading to respiratory and multi-organ failure in COVID-19 patients. We used a multiplex immunoassay to systematically profile and compare 65 inflammatory cytokines/chemokines/growth factors in plasma samples from 24 hospitalized (severe/critical) COVID-19 patients, 14 mild/moderate cases, and 13 healthy controls (HCs). Patients with severe/critical and mild/moderate COVID-19 had significantly higher plasma levels of 20 analytes than HCs. Surprisingly, only one cytokine (MIF) was among these altered analytes, while the rest were chemokines and growth factors. In addition, only MMP-1 and VEGF-A were significantly elevated in hospitalized COVID-19 patients when compared to mild/moderate cases. Given that excessive MMP-1 plays a central role in tissue destruction in a wide variety of vascular diseases and that elevated VEGF-A, an EC activation marker, increases vascular permeability, we further studied MMP-1 enzymatic activity and other EC activation markers such as soluble forms of CD146, ICAM-1, and VCAM-1. We found that plasma MMP-1 enzymatic activity and plasma levels of MMP-1 and EC activation markers were highly dysregulated in COVID-19 patients. Some dysregulations were associated with patients’ age or gender, but not with race. Our results demonstrate that COVID-19 patients have distinct inflammatory profiles that are distinguished from the cytokine storms in other human diseases. Excessive MMP-1 and hyperactivation of ECs occur in COVID-19 patients and are associated with the severity of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially funded by NIAAA grant (UH2AA026218 to Q.Y.) and the grant (OPP1035237 to Q.Y.) from the Bill & Melinda Gates Foundation. This publication was made possible, in part, with support from the Indiana Biobank and the Indiana Clinical and Translational Sciences Institute (CTSI) funded by the National Institutes of Health (UL1TR002529), National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed with the approval of the Institutional Review Boards at Indiana University School of Medicine. Blood samples were drawn after each participant provided a written informed consent form.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We would wish to make our results available to the community of scientists interested in COVID-19. We would also welcome collaboration with others who could make use of the strategies and reagents developed in this project. As researchers and educators, we would also make our findings available to the public.
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- ALC
- absolute lymphocyte count
- APMA
- amino-phenyl mercuric acetate
- ARDS
- acute respiratory distress syndrome
- CAR
- chimeric antigen receptor
- COVID-19
- coronavirus disease 2019
- CEC
- circulating endothelial cell
- CRP
- C-reactive protein
- CSS
- cytokine storm syndrome
- EC
- endothelial cell
- ESR
- erythrocyte sedimentation rate
- GVHD
- graft-versus-host disease
- HC
- healthy controls
- HGF
- hepatocyte growth factor
- ICAM-1
- intercellular adhesion molecule 1
- I-FABP
- intestinal fatty acid binding protein
- ICU
- intensive care unit
- DIC
- disseminated intravascular coagulation
- MERS-CoV
- East respiratory syndrome coronavirus
- MIF
- macrophage migration inhibitory factor
- MMP-1
- matrix metalloproteinase-1
- NRP1
- neuropilin-1
- NT-proBNP
- N-terminal (NT)-pro hormone B-type natriuretic peptide
- PAR1
- protease-activated receptor-1
- PBS
- phosphate buffered saline
- PBMC
- peripheral blood mononuclear cell
- RFU
- relative fluorescence unit
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SD
- standard deviation
- SEM
- standard error of the mean
- TMPRSS2
- transmembrane protease serine 2
- VCAM-1
- vascular cell adhesion molecule 1
- VEGF-A
- vascular endothelial growth factor A.
